{
    "clinical_study": {
        "@rank": "67285", 
        "arm_group": {
            "arm_group_label": "DCV 3DAA FDC + BMS-791325", 
            "arm_group_type": "Experimental", 
            "description": "Group A to D: DCV 3DAA FDC + BMS-791325 oral tablets on specific days\nGroup E: DCV 3DAA FDC + BMS-791325 oral tablets on specific days"
        }, 
        "brief_summary": {
            "textblock": "Assess the effect of renal function on the blood levels of DCV, ASV, BMS-791325."
        }, 
        "brief_title": "To Assess the Effect of Renal Impairment on the Blood Levels of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325 After Multiple Doses of a Fixed Dose Combination Tablet", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatitis C", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis C"
            ]
        }, 
        "detailed_description": {
            "textblock": "IND Number: 79,599/101,943\n\n      Primary Purpose: Other - Phase 1 Clinical Pharmacology  study to determine the effect  of\n      renal impairment on the exposure of DCV, ASV, BMS-791325 (fixed dosed combination) and\n      BMS-791325 given in multiple doses\n\n      Fixed dose combination (FDC)\n\n      Fixed Dose Combination of Daclatasvir, Asunaprevir and BMS-791325 (DCV 3DAA FDC)"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "For more information regarding BMS clinical trial participation, please visit\n        www.BMSStudyConnect.com\n\n        Inclusion Criteria:\n\n          -  Subjects in Group A must be in good health and have normal renal function\n\n          -  Subjects in Groups B-E may  have clinical, Electrocardiogram (ECG) and laboratory\n             findings consistent with their degree of renal dysfunction\n\n          -  Women of childbearing potential (WOCBP) and male participants must agree to follow\n             the required contraceptive methods\n\n        Exclusion Criteria:\n\n          -  Subjects in Group A must not have any significant acute or chronic illnesses\n\n          -  Subjects in Groups B-E must not have uncontrolled or unstable cardiovascular,\n             respiratory, hepatic, gastrointestinal, endocrine, hematopoietic, and/or neurological\n             disease within 6 months of screening\n\n          -  Subjects in Groups B-E may not have evidence of rapidly deteriorating renal function,\n             defined as a screening creatinine clearance (CLcr) which has decreased from a\n             previous CLcr by 50% within the last 3 months\n\n          -  Prior exposure to DCV, ASV or BMS-791325 within 3 months prior to study drug\n             administration"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02108639", 
            "org_study_id": "AI443-110"
        }, 
        "intervention": [
            {
                "arm_group_label": "DCV 3DAA FDC + BMS-791325", 
                "intervention_name": "DCV 3DAA FDC", 
                "intervention_type": "Drug", 
                "other_name": "Fixed Dose Combination of Daclatasvir, Asunaprevir and BMS-791325"
            }, 
            {
                "arm_group_label": "DCV 3DAA FDC + BMS-791325", 
                "intervention_name": "BMS-791325", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 7, 2014", 
        "link": [
            {
                "description": "BMS Clinical Trial Information", 
                "url": "http://ctr.bms.com/ctd/start.do"
            }, 
            {
                "description": "BMS clinical trial educational resource", 
                "url": "http://www.bms.com/studyconnect/Pages/home.aspx"
            }, 
            {
                "description": "Investigator Inquiry form", 
                "url": "http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"
            }, 
            {
                "description": "FDA Safety Alerts and Recalls", 
                "url": "http://www.fda.gov/MEDWATCH/safety.htm"
            }
        ], 
        "location": [
            {
                "contact": {
                    "last_name": "Kenneth C Lasseter, Site 0003"
                }, 
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33014"
                    }, 
                    "name": "Clinical Pharmacology Of Miami Inc."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Thomas C Marbury, Site 0002"
                }, 
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32809"
                    }, 
                    "name": "Orlando Clinical Research Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Jolene Berg, Site 0001"
                }, 
                "facility": {
                    "address": {
                        "city": "Minneapolis", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55404"
                    }, 
                    "name": "Davita Clinical Research"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "William Smith, Site 0004"
                }, 
                "facility": {
                    "address": {
                        "city": "Knoxville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37920"
                    }, 
                    "name": "New Orleans Center For Clinical Research - Knoxville"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-label, Multiple-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Fixed Dose Combination Formulation of DCV, ASV, and BMS-791325 in Subjects With Normal Renal Function and Subjects With Mild, Moderate, Severe, and End-stage Renal Dysfunction", 
        "overall_contact": {
            "email": "Clinical.Trials@bms.com", 
            "last_name": "Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:"
        }, 
        "overall_contact_backup": {
            "last_name": "First line of the email MUST contain NCT# and Site #."
        }, 
        "overall_official": {
            "affiliation": "Bristol-Myers Squibb", 
            "last_name": "Bristol-Myers Squibb", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Maximum observed plasma concentration (Cmax) for DCV, ASV, BMS-791325 and BMS-794712", 
                "safety_issue": "No", 
                "time_frame": "For Groups A-D: Day 1 to Day 10 and for Group E: Day 1 to Day 12"
            }, 
            {
                "measure": "Area under the concentration-time curve in 1 dosing interval (AUC(TAU)) for DCV, ASV, BMS-791325 and BMS-794712", 
                "safety_issue": "No", 
                "time_frame": "For Groups A-D: Day 1 to Day 10 and for Group E: Day 1 to Day 12"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02108639"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Concentration at 12 hours (C12) for (DCV, ASV, BMS-791325) and BMS-948158", 
                "safety_issue": "No", 
                "time_frame": "For Groups A-D: Day 1 to Day 11 and for Group E: Day 1 to Day 13"
            }, 
            {
                "measure": "Time of maximum observed concentration (Tmax) for (DCV, ASV, BMS-791325) and BMS-948158", 
                "safety_issue": "No", 
                "time_frame": "For Groups A-D: Day 1 to Day 11 and for Group E: Day 1 to Day 13"
            }, 
            {
                "measure": "Apparent total body clearance (CLT/F) for (DCV, ASV and BMS-791325 only)", 
                "safety_issue": "No", 
                "time_frame": "For Groups A-D: Day 1 to Day 11 and for Group E: Day 1 to Day 13"
            }, 
            {
                "measure": "Trough observed plasma concentration (Ctrough) for (DCV, ASV, BMS-791325), BMS-794712 and BMS-948158", 
                "safety_issue": "No", 
                "time_frame": "For Groups A-D: Day 1 to Day 11 and for Group E: Day 1 to Day 13"
            }, 
            {
                "description": "BMS-948158 may also be analyzed", 
                "measure": "Cmax fraction unbound (Cmaxfu) for (DCV, ASV, BMS-791325), BMS-794712 and BMS-948158", 
                "safety_issue": "No", 
                "time_frame": "For Groups A-D: Day 1 to Day 11 and for Group E: Day 1 to Day 13"
            }, 
            {
                "description": "BMS-948158 may also be analyzed", 
                "measure": "AUC(TAU) fraction unbound (AUC(TAU) fu) for (DCV, ASV, BMS-791325), BMS-794712 and BMS-948158", 
                "safety_issue": "No", 
                "time_frame": "For Groups A-D: Day 1 to Day 11 and for Group E: Day 1 to Day 13"
            }, 
            {
                "measure": "Protein Binding for DCV, ASV, BMS-791325 and BMS-794712", 
                "safety_issue": "No", 
                "time_frame": "1 and 4 hours postdose on Day 10 (all subjects) and Day 12 (Group E only)"
            }, 
            {
                "measure": "Total amount recovered in urine (URt) for (DCV, ASV, BMS-791325) and BMS-794712", 
                "safety_issue": "No", 
                "time_frame": "For Groups A-D: Day 1 to Day 11 and for Group E: Day 1 to Day 13"
            }, 
            {
                "measure": "Total percent of administered dose recovered in urine (%URt) for (DCV, ASV, and BMS-791325 only)", 
                "safety_issue": "No", 
                "time_frame": "For Groups A-D: Day 1 to Day 11 and for Group E: Day 1 to Day 13"
            }, 
            {
                "measure": "Renal clearance (CLR) for DCV, ASV, BMS-791325, and BMS-794712", 
                "safety_issue": "No", 
                "time_frame": "For Groups A-D: Day 1 to Day 11 and for Group E: Day 1 to Day 13"
            }, 
            {
                "measure": "Maximum observed concentration (Cmax) for BMS-948158", 
                "safety_issue": "No", 
                "time_frame": "For Groups A-D: Day 1 to Day 11 and for Group E: Day 1 to Day 13"
            }, 
            {
                "measure": "Area under the concentration-time curve in 1 dosing interval (AUC (TAU)) for BMS-948158", 
                "safety_issue": "No", 
                "time_frame": "For Groups A-D: Day 1 to Day 11 and for Group E: Day 1 to Day 13"
            }, 
            {
                "measure": "Safety based on occurrence of Adverse Event (AEs), Serious adverse event (SAEs) and AEs leading to discontinuation", 
                "safety_issue": "Yes", 
                "time_frame": "For Groups A-D: Day 1 to Day 11 and for Group E: Day 1 to Day 13"
            }, 
            {
                "measure": "Safety based on abnormalities in vital sign measurements", 
                "safety_issue": "Yes", 
                "time_frame": "For Groups A-D: Day 1 to Day 11 and for Group E: Day 1 to Day 13"
            }, 
            {
                "measure": "Safety based on findings on ECG measurements and physical examinations", 
                "safety_issue": "Yes", 
                "time_frame": "For Groups A-D: Day 1 to Day 11 and for Group E: Day 1 to Day 13"
            }, 
            {
                "measure": "Safety based on Marked abnormalities in clinical laboratory test findings", 
                "safety_issue": "Yes", 
                "time_frame": "For Groups A-D: Day 1 to Day 11 and for Group E: Day 1 to Day 13"
            }
        ], 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}